A question vrs37. So far your posts outline your perceived concerns for the device...possible misreporting regarding trial participants, radiation leakage to other parts of the body, superior chemotherapy that other trials couldn’t access. All good as a broad spectrum of views is healthy.
It would be curious to share though what made you invest in the company if you hold such apprehensions? There were a bunch of non holding posters pre EU approval that pushed these ideas to the hilt, quoting Meddev with an accompanying “no chance for CE Mark” mantra. You sound like a mild version albeit with a “held” status.
Ann: Oncosil breakthrough device receives CE Marking approval, page-107
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.020(2.00%) |
Mkt cap ! $14.50M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 99.5¢ | $44.55K | 44.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 192 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 6234 | 1 |
View Market Depth
| Last trade - 15.48pm 25/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |